AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
AstraZeneca is the second-biggest listed company in the UK, with a market value of nearly £196bn. Photograph: David Levene/The GuardianView image in fullscreenAstraZeneca is the second-biggest listed company in the UK, with a market value of nearly £196bn. Zeneca had been spun off from Imperial Chemical Industries five years earlier.Under Soriot, the FTSE 100 company fended off a hostile bid from its US rival Pfizer in 2014 that valued AstraZeneca at almost £70bn.
- ▪AstraZeneca is the second-biggest listed company in the UK, with a market value of nearly £196bn.
- ▪Photograph: David Levene/The GuardianView image in fullscreenAstraZeneca is the second-biggest listed company in the UK, with a market value of nearly £196bn.
- ▪Zeneca had been spun off from Imperial Chemical Industries five years earlier.Under Soriot, the FTSE 100 company fended off a hostile bid from its US rival Pfizer in 2014 that valued AstraZeneca at almost £70bn.
4 outlets in our directory ran this story, first to last over 10 hours. Coverage spans 2 points on the political spectrum — 1 centre, 1 right.
- ▪ AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report — New York Post
- ▪ AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports - Reuters — Google News
- ▪ AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up — International homepage
The Guardian — World publishes from United Kingdom and files mainly under world. We currently carry 2,564 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Guardian — World |
| Canonical URL | https://www.theguardian.com/business/2026/aug/03/astrazeneca-talks-bristol-myers-squibb-merger-pharmaceuticals |
| Publication time | Mon, 03 Aug 2026 07:08:12 GMT |
| Retrieval time | 2026-08-03T07:20:44.039Z |
| Last seen | 2026-08-03T07:20:44.039Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 0D428S38C0jP · 5 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
AstraZeneca is the second-biggest listed company in the UK, with a market value of nearly £196bn. Photograph: David Levene/The GuardianView image in fullscreenAstraZeneca is the second-biggest listed company in the UK, with a market value of nearly £196bn. Photograph: David Levene/The GuardianAstraZenecaAstraZeneca holds talks with Bristol Myers Squibb on $400bn mergerTie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Julia KolleweMon 3 Aug 2026 03.08 EDTFirst published on Mon 3 Aug 2026 03.05 EDTSharePrefer the Guardian on GoogleBritain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Guardian — World.
Discussion
0 commentsMore from The Guardian — World
